7TM Pharma And Synaptic Pharmaceutical, (SNAP) A Wholly Owned Subsidiary Of Lundbeck, Announces Collaborative Agreement On Novel Drug Targets
10/19/2005 5:09:40 PM
7TM Pharma and Synaptic have signed a collaborative agreement under which 7TM Pharma will apply its structure based drug discovery approach, Site-Directed Drug Discovery®, on 7TM receptors provided by Synaptic. Under the agreement, Synaptic has granted 7TM Pharma access to selected 7TM receptor drug targets with the right to pursue drug discovery and development on these drug targets. Synaptic has received options to obtain the exclusive rights to resulting drug discovery and development projects within Central Nervous System disorders against upfront payment, milestones and royalties.
comments powered by